Background
Lynch Syndrome
LYNCH SYNDROME
Edited by: Toni T. Seppälä, Helsinki University Central Hospital, FinlandReviewed by: Erdogan Pekcan Erkan, Tampere University, Finland; Bryson Katona, University of Pennsylvania, United StatesRecent clinical trial data from Lynch Syndrome (LS) carriers demonstrated that naproxen administered for 6-months is a safe primary chemoprevention that promotes activation of different resident immune cell types without increasing lymphoid cellularity. While intriguing, the precise immune cell types enriched by naproxen remained unanswered. Here, we have utilized cutting-edge technology to elucidate the immune cell types activated by naproxen in mucosal tissue of LS patients.